Summary

The aim of this project, which was commissioned by NICE through the NIHR HTA Programme as part of the NICE’s Single Technology Appraisal process, was to review the evidence for the clinical and cost-effectiveness of Aflibercept for treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO). The clinical evidence submitted by the company (Bayer Pharma AG) responsible for manufacturing Aflibercept (Eylea) consisted of one RCT involving Aflibercept, VIBRANT, and eight studies involving relevant comparator treatments (laser photocoagulation therapy, ranibizumab or dexamethasone). The Aberdeen HTA Group acted as the Evidence Review Group (ERG) for the project and provided an independent critique of the clinical and cost-effectiveness evidence submitted by the company.

After taking into consideration the company submission and the findings of the ERG’s critique, NICE released a technology appraisal guidance (TA409, September 2016). Aflibercept is recommended by NICE as an option, within its marketing authorisation, for treating visual impairment in adults caused by macular oedema after branch retinal vein occlusion, only if the company provides Aflibercept in line with the commercial access agreement with NHS England.

https://www.nice.org.uk/guidance/ta409

Contact

Miriam Brazzelli; m.brazzelli@abdn.ac.uk

Status

Completed

Publications

Scott, N, Cummins, E, Cruickshank, M, Fraser, C, Lois, N, Brazzelli, M. Aflibercept for treating visual impairment due to macular oedema secondary to branch vein occlusion: a single technology appraisal. . Evidence Review Group report in support of the NICE STA Programme. . University of Aberdeen: Health Services Research Unit; 2016 URL: https://www.nice.org.uk/guidance/ta409/documents/committee-papers-3